Neena Bitritto-Garg, CFA’s Post

More on the use of #AI and #MachineLearning to enhance #ClinicalTrials and #patient selection in #NASH and #NAFLD #DrugDevelopment by Hepion Pharmaceuticals here achine learning (“ML”) to enrich NASH clinical trials and for NASH patient selection

Congratulations Zealand Pharma on your first 25 years. A real Biotech success story: FROM TECHNOLOGY THAT ‘FAILED’ to PUBLICALLY TRADED COMPANY with several DRUGS ON THE MARKET. Late 1997 Florian Schönharting asked me to look at a technology which potentially could form the basis for one of the first companies to be funded through BankInvest BBU-I, the first #Biotech VC fund in DK, which we had just persuaded Institutional Investors to invest in (367 MDKK – a lot of money back then). Florian called the prospective company for Due-Pep after the inventor Bjarne Due Larsen backed by Leif Helth Jensen (Helth Care), Lars Hellerung Christiansen, and Dan Buxbom. By adding 5 Lys residues to the 5AA Met-Enkephalin they could make it orally active (n=1½). I was surprised and encouraged/challenged them to do it with substance P (11 AA) and #GLP-1 (~30 AA) to show that the technology was actually scalable. Importantly, Florian gathered a great team including Eva Steiness as CEO and two other former Lundbeck people, John Hyttel, and @David Knott plus also Jørgen Søberg Petersen and Jens H. Mikkelsen ('Jens Damsgaard M') to make: Zealand Pharmaceuticals’ - a company destined to revolutionize biopharmaceuticals by making peptides ORALLY ACTIVE – and we, i.e. BankInvest BBU-I invested happily in the new company, based on the - at that time still only - 1½ Met-enkephalin oral bioavailability curve(s). As feared, GLP-1 - or rather exendin-4 - did not become orally active by adding the 5 Lys residues ………. But, it had a halflife of 2-3 hours (sub.cut.) and the SIP'ed peptide was - importantly - PATENTABLE. And, at that time companies like Sanofi Aventis badly needed to get into the GLP-1 agonist field to try to compete with #Amylin Pharma's #Exenatide, #Byetta(r) - also exendin-4 - and Novo Nordisk’s #liraglutide to become, #Victoza® (prolonged GLP-1) and so Sanofi eventually bought Zealands’ #Lixisenatide to become #Lyxumia. The rest is History! - now 25 years long and still counting. Biotech Lesson: A GREAT TEAM is often more important than a great technology – both, is obviously really great.

https://lnkd.in/g6N2dDBh Key Insights: • Gilead has expanded its portfolio with the addition of Seladelpar, a PPARδ agonist aimed at treating Primary Biliary Cholangitis (PBC) • Seladelpar is undergoing FDA priority review, with anticipated approval in the U.S. by the third quarter of 2024 Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #HealthTrends #Insights #HealthIndustry #HealthInnovation #gilead #cymabay #acquisition #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

As more clinical trials in #Psychedelics emerge, it’s important to design studies with the patient’s condition in mind. Make sure to check out my team member’s presentation at the Psychedelic Therapeutics & Drug Development Conference to learn more! https://bit.ly/4bnRvXY

As more clinical trials in #Psychedelics emerge, it’s important to design studies with the patient’s condition in mind. Make sure to check out my team member’s presentation at the Psychedelic Therapeutics & Drug Development Conference to learn more! https://bit.ly/4bnRvXY

As more clinical trials in #Psychedelics emerge, it’s important to design studies with the patient’s condition in mind. Make sure to check out my team member’s presentation at the Psychedelic Therapeutics & Drug Development Conference to learn more! https://bit.ly/4bnRvXY

As more clinical trials in #Psychedelics emerge, it’s important to design studies with the patient’s condition in mind. Make sure to check out my team member’s presentation at the Psychedelic Therapeutics & Drug Development Conference to learn more! https://bit.ly/4bnRvXY

Idiopathic Membranous Nephropathy Market to Expand at a Substantial Growth Rate During the Forecast Period (2023-32) - Asserts DelveInsight | Cerium Pharmaceuticals, Roche, BeiGene, MorphoSys, I-Mab Biopharma, Human Immunology Biosciences https://lnkd.in/g-sx6HC3 #marketanalysis #marketresearch #marketresearchreports #businessintelligence

𝐍𝐞𝐰𝐬 𝐚𝐛𝐨𝐮𝐭 𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 Personalize medicine based on peptide has made great progress in recent years. As more and more clinical projects were initiated the demand for small scale GMP grade peptides was also picking up quickly. Hence, Intavis Peptide Services decided in 2019 to build 𝐚 𝐆𝐌𝐏 𝐀𝐏𝐈 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐲. Lo and behold, we are on schedule and eagerly await the opening ceremonies planned for Q4 of 2024. If you are you planning any 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬 𝐨𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, don’t hesitate to check out 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞. #gmp #drugdevelopment #peptides #clinicaltrials #intavis

By offering these end-to-end services across the drug lifecycle, an integrated CRDMO platform,Chinese Peptide Company can provide a seamless and efficient pathway for the development, manufacturing, and commercialization of peptide and oligonucleotide therapeutics, ultimately helping clients bring their innovative treatments to market faster and more effectively. For more information, please visit：https://lnkd.in/gmNEVsqk #Peptide #oligonucleotides #manufacturing #CPC #Chinesepeptidecompany #cgmp #peptides #cdmo #api #drugdevelopment #peptidesynthesis #peptidetherapeutics #GMP